Biden’s Omicron Booster Campaign Faces Fatigue, Efficacy Doubts

The Biden administration should make infection severity a focus of its Covid-19 booster campaign as limited efficacy data and cost-shifting threatens to hinder uptake of the latest shot, infectious disease doctors and policy analysts say.

Federal regulators last week cleared the two omicron-targeting shots from Moderna Inc. and Pfizer Inc. after a panel of outside vaccine experts recommended them in two 13-1 votes. The Centers for Disease Control and Prevention cited a joint survey with the University of Iowa and the RAND Corporation that found 72% of eligible adults said they “definitely” or “probably” will get an updated booster.

But ...